Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lissoni

Showing results (21-30 of 287) with videos related to

Pageof 29
Sort By:
Tumori|June 30, 1993
Prevention by L-carnitine of interleukin-2 related cardiac toxicity during cancer immunotherapyP Lissoni, M A Galli, G Tancini, et al.
Anticancer Research|April 13, 2001
A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 aloneP Lissoni, F Rovelli, N Baiocco, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 24, 1999
Transient increase of plasma interleukin-6 after infusion of recombinant tumor necrosis factor alpha in advanced cancer patientsB Zubelewicz, W Romanowski, B Braczkowska, et al.
Annals of the New York Academy of Sciences|September 30, 1995
Modulation of tumor necrosis factor-alpha (TNF-alpha) toxicity by the pineal hormone melatonin (MLT) in metastatic solid tumor patientsR Braczkowski, B Zubelewicz, W Romanowski, et al.
Tumori|November 1, 1995
Endocrine effects of granulocyte colony-stimulating factor in cancer patientsF Rovelli, S Barni, G Tancini, et al.
Tumori|June 30, 1988
Endocrine and clinical effects of an LHRH analogue in pretreated advanced breast cancerP Lissoni, S Barni, S Crispino, et al.
Haematologica|September 1, 1991
Thrombocytosis, neutrophilia and anemia during interleukin-2 therapyF Rossini, F Brivio, S Mingozzi, et al.
Journal of Endocrinological Investigation|February 1, 1990
A study of pineal-prolactin interaction: prolactin response to an acute melatonin injection in patients with hyperprolactinemiaP Lissoni, E Mainini, C Mazzi, et al.
Tumori|December 31, 1993
Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance statusP Lissoni, F Brivio, A Ardizzoia, et al.
The International Journal of Biological Markers|October 1, 1988
Soluble interleukin-2 receptor levels in Hodgkin's disease: preliminary considerations about their prognostic significanceP Lissoni, S Barni, F Rovelli, et al.
Pageof 29

Showing results (21-30 of 287) with videos related to

Sort By:
Pageof 29
Tumori|June 30, 1993
Prevention by L-carnitine of interleukin-2 related cardiac toxicity during cancer immunotherapyP Lissoni, M A Galli, G Tancini, et al.
Anticancer Research|April 13, 2001
A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 aloneP Lissoni, F Rovelli, N Baiocco, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 24, 1999
Transient increase of plasma interleukin-6 after infusion of recombinant tumor necrosis factor alpha in advanced cancer patientsB Zubelewicz, W Romanowski, B Braczkowska, et al.
Annals of the New York Academy of Sciences|September 30, 1995
Modulation of tumor necrosis factor-alpha (TNF-alpha) toxicity by the pineal hormone melatonin (MLT) in metastatic solid tumor patientsR Braczkowski, B Zubelewicz, W Romanowski, et al.
Tumori|November 1, 1995
Endocrine effects of granulocyte colony-stimulating factor in cancer patientsF Rovelli, S Barni, G Tancini, et al.
Tumori|June 30, 1988
Endocrine and clinical effects of an LHRH analogue in pretreated advanced breast cancerP Lissoni, S Barni, S Crispino, et al.
Haematologica|September 1, 1991
Thrombocytosis, neutrophilia and anemia during interleukin-2 therapyF Rossini, F Brivio, S Mingozzi, et al.
Journal of Endocrinological Investigation|February 1, 1990
A study of pineal-prolactin interaction: prolactin response to an acute melatonin injection in patients with hyperprolactinemiaP Lissoni, E Mainini, C Mazzi, et al.
Tumori|December 31, 1993
Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance statusP Lissoni, F Brivio, A Ardizzoia, et al.
The International Journal of Biological Markers|October 1, 1988
Soluble interleukin-2 receptor levels in Hodgkin's disease: preliminary considerations about their prognostic significanceP Lissoni, S Barni, F Rovelli, et al.
Pageof 29